Table 2 Analysis of clinical characteristics between the CMV infection and non-CMV infection groups
Variable | CMV infection (n = 64) | Non-CMV infection (n = 51) | Pa |
|---|---|---|---|
Clinical manifestation | |||
 Abdominal pain |  |  | 0.043 |
  Yes | 50 (78.1%) | 31 (60.8%) |  |
  No | 14 (21.9%) | 20 (39.2%) |  |
Stool frequency | 9.7 ± 6.4 | 8.0 ± 4.7 | 0.127 |
 Hematochezia |  |  | 0.746 |
  Yes | 59 (92.2%) | 45 (90.0%) |  |
  No | 5 (7.8%) | 5 (10.0%) |  |
 Fever |  |  | 0.005 |
  Yes | 36 (56.3%) | 15 (29.4%) |  |
  No | 28 (43.8%) | 36 (70.6%) |  |
Parenteral presentations | |||
 Oral ulcer |  |  | 0.002 |
  Yes | 14 (21.9%) | 1 (2.0%) |  |
  No | 50 (78.1%) | 50 (98.0%) |  |
 Vulvar ulcer |  |  | 1.000 |
  Yes | 1 (1.6%) | 0 |  |
  No | 63 (98.4%) | 51 (100%) |  |
 Arthritis |  |  | 0.115 |
  Yes | 6 (9.4%) | 10 (19.6%) |  |
  No | 58 (90.6%) | 41 (80.4%) |  |
 Gallstone |  |  | 0.628 |
  Yes | 3 (4.7%) | 1 (2.0%) |  |
  No | 61 (95.3%) | 50 (98.0%) |  |
 Eye lesion |  |  | 0.584 |
  Yes | 1 (1.6%) | 2 (3.9%) |  |
  No | 63 (98.4%) | 49 (96.1%) |  |
 Thromboembolism |  |  | 0.321 |
  Yes | 1 (1.6%) | 3 (5.9%) |  |
  No | 63 (98.4%) | 48 (94.1%) |  |
Complications | |||
 Intestinal obstruction |  |  | 1.000 |
  Yes | 3 (4.7%) | 2 (3.9%) |  |
  No | 61 (95.3%) | 49 (96.1%) |  |
 Intestinal perforation |  |  | 1.000 |
  Yes | 1 (1.6%) | 0 |  |
  No | 63 (98.4%) | 50 (100%) |  |
 Gastrointestinal bleeding |  |  | 0.380 |
  Yes | 4 (6.3%) | 1 (2.0%) |  |
  No | 60 (93.7%) | 50 (98.0%) |  |
 Toxic megacolon |  |  | 1.000 |
  Yes | 1 (1.6%) | 0 |  |
  No | 63 (98.4%) | 51 (100%) |  |